O. Eipel

[Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies].

G. Kovács, M. Csóka, K. Csordás, 2011, Orvosi Hetilap.

The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy

A. Ferenczy, A. Ponyi, G. Kovács, 2013, International Journal of Hematology.

Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia

G. Kovács, K. Csordás, O. Eipel, 2013, Anti-cancer drugs.

Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL

G. Kovács, M. Csóka, K. Németh, 2016, Journal of pediatric hematology/oncology.

Associations of novel genetic variations in the folate‐related and ARID5B genes with the pharmacokinetics and toxicity of high‐dose methotrexate in paediatric acute lymphoblastic leukaemia

A. Harnos, Á. Semsei, C. Szalai, 2014, British journal of haematology.

Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma

A. Arany, P. Antal, A. Gézsi, 2016, Oncotarget.

Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma

Judit Müller, G. Kovács, K. Nemes, 2012, Journal of Cancer Research and Clinical Oncology.